Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma. (November 2020)

• Record Type: Journal Article
• Authors: Zhang, Hao; Sun, Minli; Zhou, Di; Gorur, Aysegul; Sun, Zhirong; Zeng, Weian; Cata, Juan P.; Chen, Wankun; Miao, Changhong
• Is Part Of: British journal of anaesthesia. Volume 125:Number 5(2020)
• Page Start: 722
• Page End: 729
• Publication Date: 2020-11
• Subjects: disease-free survival -- laryngeal squamous cell carcinoma -- mu-opioid receptor -- OPRM1 -- overall survival; Anesthesiology -- Periodicals; Anesthesia -- Periodicals; 617.9605
• DOI: 10.1016/j.bja.2020.07.051
• Languages: English
• ISSNs: 0007-0912

Abstract

Abstract: Background: Expression of the mu-opioid receptor (MOR) is associated with poor long-term outcomes in various types of cancer. The association between MOR expression and clinical outcomes in laryngeal squamous cell carcinoma (LSCC) is not clear. Methods: This retrospective study included patients who underwent laryngectomy for LSCC. The expression pattern of the MOR protein and OPRM1 gene in tumours and corresponding adjacent non-carcinoma specimens was measured. Propensity score matching was used to minimise bias. The primary endpoints were overall survival (OS) and disease-free survival (DFS). The secondary endpoints were intraoperative sufentanil consumption, grade of surgical complications according to the Clavien-Dindo classification, and hospital length of stay. Results: A total of 207 LSCC patients were enrolled. After propensity score matching, there was a significant difference in DFS between groups at 1, 3, and 5 yr (60.2% vs 81.2%, P =0.019; 39.4% vs 50.2%, P =0.026; 37.5% vs 42.5%, P =0.023, respectively) in patients with high MOR expression. The OS rates at 1, 3, and 5 yr were significantly lower in the high MOR expression group (81.2% vs 93.2%, P =0.027; 57.7% vs 78.3%, P <0.001; 42.5% vs 60.3%, P <0.001, respectively). The multivariate analysis indicated that high MOR expression was associated with worse DFS and OS (hazard ratio: 1.52, 95% confidence interval: 1.07, 2.25, P =0.034; hazard ratio: 1.42, 95% confidence interval: 1.17, 2.34, P =0.032). Conclusion: High MOR expression may be associated with poor prognosis in patients with LSCC, suggesting that MOR could be used as a valuable molecular biomarker to predict prognosis of LSCC patients.